Cargando…

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

BACKGROUND: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Hao, Liu, Si-Yang, Zhou, Jia-Ying, Xu, Jin-Tian, Zhang, Huang-Kai, Yan, Hong-Hong, Huan, Jiao-Jiao, Dai, Ping-Ping, Xu, Chong-Rui, Su, Jian, Guan, Yan-Fang, Yi, Xin, Yu, Rong-Shan, Zhong, Wen-Zhao, Wu, Yi-Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494676/ https://www.ncbi.nlm.nih.gov/pubmed/32927274 http://dx.doi.org/10.1016/j.ebiom.2020.102990

Ejemplares similares

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation
por: Zeng, Dejun, et al.
Publicado: (2021)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

Mesonephric Adenocarcinoma of the Vagina Harboring TP53 Mutation
por: Lee, Hyunjee, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
por: Cao, Jia-Zheng, et al.
Publicado: (2022)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2016)

Investigation on the Potential Correlation Between TP53 and Esophageal Cancer
por: Yao, Lihua, et al.
Publicado: (2021)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

MIR-4507 Targets TP53 to Facilitate the Malignant Progression of Non‐small‐cell Lung Cancer
por: Zhao, MengYang, et al.
Publicado: (2021)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
por: Clarke, Stephen L., et al.
Publicado: (2019)

TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma
por: Somerville, Tim D.D., et al.
Publicado: (2018)

A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters
por: Wang, Wei, et al.
Publicado: (2023)

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis
por: Li, He, et al.
Publicado: (2023)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes
por: Coradini, Danila, et al.
Publicado: (2012)

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes
por: Thota, Ramya, et al.
Publicado: (2021)

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
por: Ragu, Mohana Eswari, et al.
Publicado: (2023)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia
por: Yan, Bowen, et al.
Publicado: (2020)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy
por: Pan, Yi-Hui, et al.
Publicado: (2021)

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition
por: Lyu, Qiong, et al.
Publicado: (2020)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

Clinical and prognostic implications of an immune‐related risk model based on TP53 status in lung adenocarcinoma
por: Song, Xuming, et al.
Publicado: (2021)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Discrimination of ground‐glass nodular lung adenocarcinoma pathological subtypes via transfer learning: A multicenter study
por: Fu, Chun‐Long, et al.
Publicado: (2023)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

The African-centric P47S Variant of TP53 Confers Immune Dysregulation and Impaired Response to Immune Checkpoint Inhibition
por: Stieg, David C., et al.
Publicado: (2023)

STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation
por: Hu, Shanshan, et al.
Publicado: (2020)

HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport
por: Luo, Peihua, et al.
Publicado: (2018)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8cm4hr8tamvrsbp04jip6f28i7